Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple investor and scientific conferences in September and October 2026, including Wells Fargo and Baird healthcare investor events with a webcasted fireside chat, and several retina-focused meetings where Phase 3 SOL-1 trial results for OTX-TKI in neovascular AMD will be presented.

Argus Sep 1 session 1 alert

+0.76% close to close 9.3x rel. volume Open Argus

Details

News Market Reaction – OCUL

$2.20B Market Cap

On Sep 1, the day this news came out, OCUL closed 0.76% above the previous close. Relative volume reached 9.3x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 1 session.

Key Figures

Participation period: September and October 2026 Wells Fargo conference: 21st Annual Healthcare Conference Retina Society meeting: 59th Annual Scientific Meeting +5 more

Participation period

September and October 2026

Upcoming investor and scientific conferences

Wells Fargo conference

21st Annual Healthcare Conference

September 10, 2026

Retina Society meeting

59th Annual Scientific Meeting

September 23–26, 2026

Trial phase

Phase 3

SOL-1 superiority trial

SOL-1 presentation

September 24, 2026

Retina Society scientific presentation

Euretina Congress

26th Congress

October 1–4, 2026

SOL-1 presentation

October 2, 2026

Euretina Congress presentation

Baird conference

September 15, 2026

Fireside chat and investor conference participation

Historical Context

5 past events · Latest: Aug 13

5 events

1. Aug 13

   Inducement grants

   24h Move

   -0.6%

   Equity inducement awards were granted to a newly appointed senior executive.

2. Aug 07

   Inducement grants

   24h Move

   +0.5%

   Equity inducement awards were granted to eight newly hired employees.

3. Aug 03

   Q2 earnings report

   24h Move

   +2.8%

   Quarterly results detailed pipeline progress, cash resources, and planned regulatory submission.

4. Jul 09

   Inducement grants

   24h Move

   -3.2%

   Equity inducement awards were granted to eleven newly hired employees.

5. Jul 01

   Investor conferences

   24h Move

   -3.6%

   The company announced July scientific and investor conference appearances.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, intravitreal, neovascular age-related macular degeneration, superiority trial

4 terms

phase 3 medical

"Results from the Phase 3 SOL-1 Superiority Trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

intravitreal medical

"Efficacy and Safety of Intravitreal Axitinib Hydrogel"

An intravitreal treatment is one given by injecting medicine directly into the gel-like center of the eye, delivering drugs straight to the site of retinal disease rather than through pills or eye drops. Investors care because this delivery method affects development costs, regulatory review, clinical risk, manufacturing and distribution complexity, and reimbursement — all factors that influence a therapy’s commercial potential.

neovascular age-related macular degeneration medical

"in Neovascular Age-related Macular Degeneration"

A progressive eye disease in older adults where abnormal blood vessels grow beneath the central retina and leak fluid or blood, quickly damaging sharp central vision used for reading and recognizing faces. For investors, it matters because it creates ongoing demand for medical treatments, diagnostics and follow-up care, and outcomes hinge on clinical trial results, regulatory approvals and reimbursement decisions that can sharply affect the value of companies developing therapies — like a chronic market need driven by a high-impact illness.

superiority trial technical

"Phase 3 SOL-1 Superiority Trial"

A superiority trial is a clinical study designed to test whether a new treatment works better than a comparator, such as an existing therapy or a placebo. Think of it like a head-to-head contest where the goal is to prove the new option outperforms the alternative; investors watch these results closely because a clear win can drive regulatory approval, market adoption and the company’s future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.

Upcoming Investor Conferences:

Wells Fargo 21^st Annual Healthcare Conference:
Date: Thursday, September 10, 2026
Ocular Therapeutix to host investor one-on-one meetings
Location: Boston, MA

Baird 2026 Global Healthcare Conference:
Date: Tuesday, September 15, 2026
Fireside Chat: 10:50 – 11:20 AM EDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York, NY

A live webcast of the Baird fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.

Upcoming Scientific Conferences:

The Retina Society 59^th Annual Scientific Meeting: September 23 – 26, 2026
Los Angeles, CA

• Presentation: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-related Macular Degeneration: Results from the Phase 3 SOL-1 Superiority Trial
  Session: AMD I
  Presentation Date/Time: Thursday, September 24, 2026, 11:30 – 11:34 AM PDT
  Presenter: Dilsher S. Dhoot, MD

Ophthalmology Futures Forums (OFF) Retina Forum 2026: September 30, 2026
Vienna, Austria

• Presentation: Ocular Therapeutix: Redefining the Retina Experience
  Presenter: Nadia K. Waheed, MD, MPH, Chief Medical Officer, Ocular Therapeutix

Euretina Innovation Spotlight (EIS): September 30, 2026
Vienna, Austria

• Presentation Title: Ocular Therapeutix: Redefining the Retina Experience
  Presenter: Peter K. Kaiser, MD, Chief Development Officer, Ocular Therapeutix

26^th Euretina Congress: October 1 - 4, 2026
Vienna, Austria

• Presentation Title: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-related Macular Degeneration: Results from the Phase 3 SOL-1 Superiority Trial 
  Session: AMD/CSC
  Session Date/Time: Friday, October 2, 2026, 13:24 – 13:30 PM CEST
  Presenter: Adnan Tufail, MBBS, MD, FRCOphth

• Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
  Symposium Date/Time: Friday, October 2, 2026, 9:45 – 10:45 AM CEST
  Faculty: Arshad M. Khanani, MD, MA, FASRS; Patricio G. Schlottmann, MD; Adnan Tufail, MBBS, MD, FRCOphth; Dilsher S. Dhoot, MD

Exact medical conference presentation times may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ocular Therapeutix (NASDAQ: OCUL) attend the Wells Fargo 21st Annual Healthcare Conference in 2026?

Ocular Therapeutix plans to attend the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026. According to Ocular Therapeutix, the company will host investor one-on-one meetings during this event in Boston, Massachusetts, as part of its September 2026 investor outreach.

What is the date and time of Ocular Therapeutix’s Baird 2026 Global Healthcare Conference fireside chat (OCUL)?

Ocular Therapeutix’s fireside chat at the Baird 2026 Global Healthcare Conference is scheduled for September 15, 2026, from 10:50 to 11:20 AM EDT. According to Ocular Therapeutix, Executive Chairman, President and CEO Pravin U. Dugel, MD, will present in New York, with a webcast and 30‑day replay.

How can investors access the Ocular Therapeutix (OCUL) Baird fireside chat webcast in September 2026?

Investors can access the Ocular Therapeutix Baird fireside chat via a live webcast on the company’s website. According to Ocular Therapeutix, the webcast will be available in the Events and Presentations section, with an archived replay accessible for at least 30 days after the presentation.

At which scientific meetings will Ocular Therapeutix present Phase 3 SOL-1 OTX-TKI data in late 2026?

Ocular Therapeutix plans to present Phase 3 SOL-1 OTX-TKI trial results at The Retina Society meeting and the 26th Euretina Congress. According to Ocular Therapeutix, these presentations focus on efficacy and safety in neovascular age-related macular degeneration, within AMD-focused scientific sessions.

When will OTX-TKI Phase 3 SOL-1 trial results be presented at The Retina Society 59th Annual Scientific Meeting?

The OTX-TKI SOL-1 results presentation at The Retina Society meeting is scheduled for Thursday, September 24, 2026, 11:30–11:34 AM PDT. According to Ocular Therapeutix, this talk occurs in the AMD I session in Los Angeles, California.

What Ocular Therapeutix presentations are planned at the 26th Euretina Congress 2026 (OCUL)?

At the 26th Euretina Congress, Ocular Therapeutix will feature a presentation on OTX-TKI Phase 3 SOL-1 results and a symposium on nAMD management. According to Ocular Therapeutix, these events occur on October 2, 2026, within AMD/CSC and durability-focused sessions in Vienna, Austria.

Which Ocular Therapeutix executives and clinicians are presenting at retina conferences in September–October 2026?

Presenters include Pravin U. Dugel, MD; Dilsher S. Dhoot, MD; Nadia K. Waheed, MD, MPH; Peter K. Kaiser, MD; and Adnan Tufail, MBBS, MD, FRCOphth. According to Ocular Therapeutix, they will speak across investor, Retina Society, OFF Retina, EIS, and Euretina events.